This inventor holds 1 USPTO granted patent. Top assignee: N.v. Organon. Active years: 2008.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2008
Title: The Innovations of Minggiang Zhang
Introduction
Minggiang Zhang is a notable inventor based in Kirkland, CA. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target neurological diseases and psychiatric disorders. His work is characterized by a focus on enhancing synaptic responses in the central nervous system.
Latest Patents
Minggiang Zhang holds a patent for his invention titled "(Pyrido/thieno)—[f]—oxazepine-5-one derivatives." This patent, which is classified under the general Formula (I), relates to derivatives that are pharmaceutically acceptable salts. The invention also encompasses pharmaceutical compositions that include these derivatives, aimed at treating neurological diseases and psychiatric disorders responsive to AMPA receptor enhancement.
Career Highlights
Zhang is currently associated with N.V. Organon, where he continues to innovate and develop new pharmaceutical solutions. His work has been instrumental in advancing treatments that address complex neurological conditions.
Collaborations
Throughout his career, Minggiang Zhang has collaborated with esteemed colleagues, including Simon James Anthony Grove and Julia Adam-Worall. These partnerships have fostered a collaborative environment that enhances the research and development process.
Conclusion
Minggiang Zhang's contributions to the field of pharmaceuticals, particularly through his patented innovations, highlight his commitment to improving treatments for neurological and psychiatric disorders. His work continues to impact the medical community positively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
